Deal Watch: AbbVie Exits Inherited CRISPR-Cas9 Team-Up With Editas
Editas regains rights to ocular programs first partnered with Allergan in 2017. Newly public F-star will focus on bispecific antibodies for cancer, TriSalus acquires oncology candidate from Dynavax.
You may also be interested in...
Deal Watch: Aging-Focused Calico Taps Start-Up Terray For Discovery
Terray/Calico tie-up will focus on small molecule discovery for diseases of aging, including cancer. Lilly, AstraZeneca sign discovery pacts with Nimbus and Illumina, respectively.
Deal Watch: AstraZeneca Out-Licenses Pneumonia Candidate, Obtains STING Inhibitors
Pharma moves Phase III-ready antibody to prevent pneumonia to Aridis, licenses preclinical STING inhibitors from F-star. Sanofi teams with SRI on AI-directed discovery, Biogen licenses BTK inhibitor from InnoCare.
Finance Watch: Three Neurology-Focused Firms Raise VC Mega-Rounds
Private Company Watch: Neuron23, Neurogene and Locanabio each raised $100m or more, highlighting increased investor interest in novel approaches to neurological diseases. Also, CRO dMed raised $100m and MinervaX brought in $57m for its vaccine to protect newborns.